Oxaliplatin activity in head and neck cancer cell lines

被引:18
作者
Espinosa, M
Martinez, M
Aguilar, JL
Mota, A
De la Garza, JG
Maldonado, V
Meléndez-Zajgla, J
机构
[1] Inst Nacl Cancerol, Mol Biol Lab, Subdirrec Invest Basica, Mexico City 14000, DF, Mexico
[2] Dept Educ Med Continua, Mexico City, DF, Mexico
[3] Dept Radiol, Mexico City, DF, Mexico
关键词
oxaliplatin; cisplatin; radiation; resistance; radiosensitization;
D O I
10.1007/s00280-004-0847-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oxaliplatin (cis-[(1R, 2R)-1,2-cyclohexanediamine-N, N'] [oxalato(2-)-O,O'] platinum; Eloxatin) is a third-generation platinum compound with a 1,2- diaminocyclohexane ( DACH) carrier ligand, which has a wide spectrum of anticancer activity in vitro systems and has displayed preclinical and clinical activity in a wide variety of tumors. To investigate its in vitro activity against head and neck cancer, we exposed two head and neck cancer cell lines to the compound, created a variant resistant to cisplatin to study cross-resistance to the compound and analyzed the potential radiosensitizing effect of the drug. We report here that oxaliplatin was cytotoxic at similar doses to cisplatin in these cells. There was no cross-resistance to cisplatin, as demonstrated by different IC50 values in these cell lines and the sensitivity to oxaliplatin of the cisplatin-resistant cell line. There was an effective radiosensitizer effect of the compound in either cell line. Additional in vitro and in vivo experimentation is warranted in order to support the use of oxaliplatin as a radiosensitizer in head and neck cancer patients.
引用
收藏
页码:301 / 305
页数:5
相关论文
共 24 条
[1]   Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine [J].
Bandala, E ;
Espinosa, M ;
Maldonado, V ;
Meléndez-Zajgla, J .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (01) :13-19
[2]   A NEW TYPE OF PAPILLOMAVIRUS DNA, ITS PRESENCE IN GENITAL CANCER BIOPSIES AND IN CELL-LINES DERIVED FROM CERVICAL-CANCER [J].
BOSHART, M ;
GISSMANN, L ;
IKENBERG, H ;
KLEINHEINZ, A ;
SCHEURLEN, W ;
HAUSEN, HZ .
EMBO JOURNAL, 1984, 3 (05) :1151-1157
[3]  
Cassidy J, 2000, INT J CLIN PRACT, V54, P399
[4]   Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck [J].
Degardin, M ;
Cappelaere, P ;
Krakowski, I ;
Fargeot, P ;
Cupissol, D ;
Brienza, S .
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1996, 32B (04) :278-279
[5]   MEAN INACTIVATION DOSE - A USEFUL CONCEPT FOR INTERCOMPARISON OF HUMAN CELL-SURVIVAL CURVES [J].
FERTIL, B ;
DERTINGER, H ;
COURDI, A ;
MALAISE, EP .
RADIATION RESEARCH, 1984, 99 (01) :73-84
[6]  
Fink D, 1997, CANCER RES, V57, P1841
[7]   ACTIVE EFFLUX SYSTEM FOR CISPLATIN IN CISPLATIN-RESISTANT HUMAN KB CELLS [J].
FUJII, R ;
MUTOH, M ;
NIWA, K ;
YAMADA, K ;
AIKOU, T ;
NAKAGAWA, M ;
KUWANO, M ;
AKIYAMA, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (04) :426-433
[8]   Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen:: The lyon R0-04 phase II trial [J].
Gérard, JP ;
Chapet, O ;
Nemoz, C ;
Romestaing, P ;
Mornex, F ;
Coquard, R ;
Barbet, N ;
Atlan, D ;
Adeleine, P ;
Freyer, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1119-1124
[9]   Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: Ddose-volume histogram analysis [J].
Gergel, TJ ;
Leichman, L ;
Nava, HR ;
Blumenson, LE ;
Loewen, GM ;
Gibbs, JF ;
Khushalani, NI ;
Leichman, CG ;
Bodnar, LM ;
Douglass, HO ;
Smith, JL ;
Kuettel, MR ;
Proulx, GM .
CANCER JOURNAL, 2002, 8 (06) :451-460
[10]  
Graham MA, 2000, CLIN CANCER RES, V6, P1205